Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.

NPJ breast cancer

Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S.
PMID: 28721379
NPJ Breast Cancer. 2016 Jun 08;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016.

The 21-gene Recurrence Score assay is validated to predict recurrence risk and chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To determine prospective breast-cancer-specific mortality (BCSM) outcomes by baseline Recurrence Score results and clinical covariates, the National Cancer Institute...

Cite
Petkov VI, Miller DP, Howlader N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2016;2:16017doi: 10.1038/npjbcancer.2016.17.
Petkov, V. I., Miller, D. P., Howlader, N., Gliner, N., Howe, W., Schussler, N., Cronin, K., Baehner, F. L., Cress, R., Deapen, D., Glaser, S. L., Hernandez, B. Y., Lynch, C. F., Mueller, L., Schwartz, A. G., Schwartz, S. M., Stroup, A., Sweeney, C., Tucker, T. C., Ward, K. C., Wiggins, C., Wu, X. C., Penberthy, L., & Shak, S. (2016). Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ breast cancer, 216017. https://doi.org/10.1038/npjbcancer.2016.17
Petkov, Valentina I, et al. "Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study." NPJ breast cancer vol. 2 (2016): 16017. doi: https://doi.org/10.1038/npjbcancer.2016.17
Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2016 Jun 08;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016. PMID: 28721379; PMCID: PMC5515329.
Copy Download .nbib Format: NLM
Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U.
PMID: 32651213
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10.

BACKGROUND: Regular use of nonsteroidal anti-inflammatory drugs (NSAID) is associated with lower risk of colorectal cancer. Genome-wide interaction analysis on single variants (G × E) has identified several SNPs that may interact with NSAIDs to confer colorectal cancer risk,...

Cite
Wang X, Su YR, Petersen PS, et al. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1800-1808doi: 10.1158/1055-9965.EPI-19-1018.
Wang, X., Su, Y. R., Petersen, P. S., Bien, S., Schmit, S. L., Drew, D. A., Albanes, D., Berndt, S. I., Brenner, H., Campbell, P. T., Casey, G., Chang-Claude, J., Gallinger, S. J., Gruber, S. B., Haile, R. W., Harrison, T. A., Hoffmeister, M., Jacobs, E. J., Jenkins, M. A., Joshi, A. D., Li, L., Lin, Y., Lindor, N. M., Marchand, L. L., Martin, V., Milne, R., Maclnnis, R., Moreno, V., Nan, H., Newcomb, P. A., Potter, J. D., Rennert, G., Rennert, H., Slattery, M. L., Thibodeau, S. N., Weinstein, S. J., Woods, M. O., Chan, A. T., White, E., Hsu, L., & Peters, U. (2020). Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(9), 1800-1808. https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang, Xiaoliang, et al. "Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,9 (2020): 1800-1808. doi: https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10. PMID: 32651213; PMCID: PMC7556991.
Copy Download .nbib Format: NLM
Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM.
PMID: 34678077
J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22.

PURPOSE: A previous cancer diagnosis is a negative consideration in evaluating patients for possible solid organ transplantation. Statistical models may improve selection of patients with cancer evaluated for transplantation.METHODS: We fitted statistical cure models for patients with cancer in...

Cite
Engels EA, Haber G, Hart A, et al. Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. J Clin Oncol. 2021;39(36):4039-4048doi: 10.1200/JCO.21.01195.
Engels, E. A., Haber, G., Hart, A., Lynch, C. F., Li, J., Pawlish, K. S., Qiao, B., Yu, K. J., & Pfeiffer, R. M. (2021). Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(36), 4039-4048. https://doi.org/10.1200/JCO.21.01195
Engels, Eric A, et al. "Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,36 (2021): 4039-4048. doi: https://doi.org/10.1200/JCO.21.01195
Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM. Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22. PMID: 34678077; PMCID: PMC8677988.
Copy Download .nbib Format: NLM
Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM.
PMID: 34678077
J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22.

PURPOSE: A previous cancer diagnosis is a negative consideration in evaluating patients for possible solid organ transplantation. Statistical models may improve selection of patients with cancer evaluated for transplantation.METHODS: We fitted statistical cure models for patients with cancer in...

Cite
Engels EA, Haber G, Hart A, et al. Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. J Clin Oncol. 2021;39(36):4039-4048doi: 10.1200/JCO.21.01195.
Engels, E. A., Haber, G., Hart, A., Lynch, C. F., Li, J., Pawlish, K. S., Qiao, B., Yu, K. J., & Pfeiffer, R. M. (2021). Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(36), 4039-4048. https://doi.org/10.1200/JCO.21.01195
Engels, Eric A, et al. "Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,36 (2021): 4039-4048. doi: https://doi.org/10.1200/JCO.21.01195
Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM. Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22. PMID: 34678077; PMCID: PMC8677988.
Copy Download .nbib Format: NLM
Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM.
PMID: 34678077
J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22.

PURPOSE: A previous cancer diagnosis is a negative consideration in evaluating patients for possible solid organ transplantation. Statistical models may improve selection of patients with cancer evaluated for transplantation.METHODS: We fitted statistical cure models for patients with cancer in...

Cite
Engels EA, Haber G, Hart A, et al. Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. J Clin Oncol. 2021;39(36):4039-4048doi: 10.1200/JCO.21.01195.
Engels, E. A., Haber, G., Hart, A., Lynch, C. F., Li, J., Pawlish, K. S., Qiao, B., Yu, K. J., & Pfeiffer, R. M. (2021). Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(36), 4039-4048. https://doi.org/10.1200/JCO.21.01195
Engels, Eric A, et al. "Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,36 (2021): 4039-4048. doi: https://doi.org/10.1200/JCO.21.01195
Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM. Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22. PMID: 34678077; PMCID: PMC8677988.
Copy Download .nbib Format: NLM
Solid Organ Transplantation and Survival among Individuals with a History of Cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM.
PMID: 33926864
Cancer Epidemiol Biomarkers Prev. 2021 Jul;30(7):1312-1319. doi: 10.1158/1055-9965.EPI-21-0044. Epub 2021 Apr 29.

BACKGROUND: The success of immunotherapy highlights a possible role for immunity in controlling cancer during remission for patients with cancer in the general population. A prior cancer diagnosis is common among solid organ transplant candidates, and immunosuppressive medications administered...

Cite
Engels EA, Haber G, Hart A, et al. Solid Organ Transplantation and Survival among Individuals with a History of Cancer. Cancer Epidemiol Biomarkers Prev. 2021;30(7):1312-1319doi: 10.1158/1055-9965.EPI-21-0044.
Engels, E. A., Haber, G., Hart, A., Lynch, C. F., Li, J., Pawlish, K. S., Qiao, B., Yu, K. J., & Pfeiffer, R. M. (2021). Solid Organ Transplantation and Survival among Individuals with a History of Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(7), 1312-1319. https://doi.org/10.1158/1055-9965.EPI-21-0044
Engels, Eric A, et al. "Solid Organ Transplantation and Survival among Individuals with a History of Cancer." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,7 (2021): 1312-1319. doi: https://doi.org/10.1158/1055-9965.EPI-21-0044
Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM. Solid Organ Transplantation and Survival among Individuals with a History of Cancer. Cancer Epidemiol Biomarkers Prev. 2021 Jul;30(7):1312-1319. doi: 10.1158/1055-9965.EPI-21-0044. Epub 2021 Apr 29. PMID: 33926864; PMCID: PMC8254777.
Copy Download .nbib Format: NLM
Utilizing SEER Cancer Registries for Population-Based Cancer Survivor Epidemiologic Studies: A Feasibility Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Gallicchio L, Elena JW, Fagan S, Carter M, Hamilton AS, Hastert TA, Hunter LL, Li J, Lynch CF, Milam J, Millar MM, Modjeski D, Paddock LE, Reed AR, Moses LB, Stroup AM, Sweeney C, Trapido EJ, West MM, Wu XC, Helzlsouer KJ.
PMID: 32651214
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1699-1709. doi: 10.1158/1055-9965.EPI-20-0153. Epub 2020 Jul 10.

BACKGROUND: While the primary role of central cancer registries in the United States is to provide vital information needed for cancer surveillance and control, these registries can also be leveraged for population-based epidemiologic studies of cancer survivors. This study...

Cite
Gallicchio L, Elena JW, Fagan S, et al. Utilizing SEER Cancer Registries for Population-Based Cancer Survivor Epidemiologic Studies: A Feasibility Study. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1699-1709doi: 10.1158/1055-9965.EPI-20-0153.
Gallicchio, L., Elena, J. W., Fagan, S., Carter, M., Hamilton, A. S., Hastert, T. A., Hunter, L. L., Li, J., Lynch, C. F., Milam, J., Millar, M. M., Modjeski, D., Paddock, L. E., Reed, A. R., Moses, L. B., Stroup, A. M., Sweeney, C., Trapido, E. J., West, M. M., Wu, X. C., & Helzlsouer, K. J. (2020). Utilizing SEER Cancer Registries for Population-Based Cancer Survivor Epidemiologic Studies: A Feasibility Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(9), 1699-1709. https://doi.org/10.1158/1055-9965.EPI-20-0153
Gallicchio, Lisa, et al. "Utilizing SEER Cancer Registries for Population-Based Cancer Survivor Epidemiologic Studies: A Feasibility Study." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,9 (2020): 1699-1709. doi: https://doi.org/10.1158/1055-9965.EPI-20-0153
Gallicchio L, Elena JW, Fagan S, Carter M, Hamilton AS, Hastert TA, Hunter LL, Li J, Lynch CF, Milam J, Millar MM, Modjeski D, Paddock LE, Reed AR, Moses LB, Stroup AM, Sweeney C, Trapido EJ, West MM, Wu XC, Helzlsouer KJ. Utilizing SEER Cancer Registries for Population-Based Cancer Survivor Epidemiologic Studies: A Feasibility Study. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1699-1709. doi: 10.1158/1055-9965.EPI-20-0153. Epub 2020 Jul 10. PMID: 32651214; PMCID: PMC7484198.
Copy Download .nbib Format: NLM
Quantitative Imaging Markers of Lung Function in a Smoking Population Distinguish COPD Subgroups with Differential Lung Cancer Risk.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Lusk CM, Wenzlaff AS, Watza D, Sieren JC, Robinette N, Walworth G, Petrich M, Neslund-Dudas C, Flynn MJ, Song T, Spizarny D, Simoff MJ, Soubani AO, Gadgeel S, Schwartz AG.
PMID: 30642838
Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):724-730. doi: 10.1158/1055-9965.EPI-18-0886. Epub 2019 Jan 14.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition with respect to onset, progression, and response to therapy. Incorporating clinical- and imaging-based features to refine COPD phenotypes provides valuable information beyond that obtained from traditional clinical evaluations. We...

Cite
Lusk CM, Wenzlaff AS, Watza D, et al. Quantitative Imaging Markers of Lung Function in a Smoking Population Distinguish COPD Subgroups with Differential Lung Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2019;28(4):724-730doi: 10.1158/1055-9965.EPI-18-0886.
Lusk, C. M., Wenzlaff, A. S., Watza, D., Sieren, J. C., Robinette, N., Walworth, G., Petrich, M., Neslund-Dudas, C., Flynn, M. J., Song, T., Spizarny, D., Simoff, M. J., Soubani, A. O., Gadgeel, S., & Schwartz, A. G. (2019). Quantitative Imaging Markers of Lung Function in a Smoking Population Distinguish COPD Subgroups with Differential Lung Cancer Risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 28(4), 724-730. https://doi.org/10.1158/1055-9965.EPI-18-0886
Lusk, Christine M, et al. "Quantitative Imaging Markers of Lung Function in a Smoking Population Distinguish COPD Subgroups with Differential Lung Cancer Risk." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 28,4 (2019): 724-730. doi: https://doi.org/10.1158/1055-9965.EPI-18-0886
Lusk CM, Wenzlaff AS, Watza D, Sieren JC, Robinette N, Walworth G, Petrich M, Neslund-Dudas C, Flynn MJ, Song T, Spizarny D, Simoff MJ, Soubani AO, Gadgeel S, Schwartz AG. Quantitative Imaging Markers of Lung Function in a Smoking Population Distinguish COPD Subgroups with Differential Lung Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):724-730. doi: 10.1158/1055-9965.EPI-18-0886. Epub 2019 Jan 14. PMID: 30642838; PMCID: PMC6449213.
Copy Download .nbib Format: NLM
Heritable Susceptibility to Breast Cancer among African-American Women in the Detroit Research on Cancer Survivors Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Purrington KS, Raychaudhuri S, Simon MS, Clark J, Ratliff V, Dyson G, Craig DB, Boerner JL, Beebe-Dimmer JL, Schwartz AG.
PMID: 32868316
Cancer Epidemiol Biomarkers Prev. 2020 Nov;29(11):2369-2375. doi: 10.1158/1055-9965.EPI-20-0564. Epub 2020 Aug 31.

BACKGROUND: African-American women have high rates of breast cancer associated with hereditary features. However, no studies have reported the prevalence of inherited variation across all genes known to be breast cancer risk factors among African-American patients with breast cancer...

Cite
Purrington KS, Raychaudhuri S, Simon MS, et al. Heritable Susceptibility to Breast Cancer among African-American Women in the Detroit Research on Cancer Survivors Study. Cancer Epidemiol Biomarkers Prev. 2020;29(11):2369-2375doi: 10.1158/1055-9965.EPI-20-0564.
Purrington, K. S., Raychaudhuri, S., Simon, M. S., Clark, J., Ratliff, V., Dyson, G., Craig, D. B., Boerner, J. L., Beebe-Dimmer, J. L., & Schwartz, A. G. (2020). Heritable Susceptibility to Breast Cancer among African-American Women in the Detroit Research on Cancer Survivors Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(11), 2369-2375. https://doi.org/10.1158/1055-9965.EPI-20-0564
Purrington, Kristen S, et al. "Heritable Susceptibility to Breast Cancer among African-American Women in the Detroit Research on Cancer Survivors Study." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,11 (2020): 2369-2375. doi: https://doi.org/10.1158/1055-9965.EPI-20-0564
Purrington KS, Raychaudhuri S, Simon MS, Clark J, Ratliff V, Dyson G, Craig DB, Boerner JL, Beebe-Dimmer JL, Schwartz AG. Heritable Susceptibility to Breast Cancer among African-American Women in the Detroit Research on Cancer Survivors Study. Cancer Epidemiol Biomarkers Prev. 2020 Nov;29(11):2369-2375. doi: 10.1158/1055-9965.EPI-20-0564. Epub 2020 Aug 31. PMID: 32868316; PMCID: PMC7642006.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries